Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection

International Journal of Antimicrobial Agents

Volumn 42, Issue 6, 2013, Pages 553-558

  Lam, Simon W ^a   Bass, Stephanie N ^a   Neuner, Elizabeth A ^a   Bauer, Seth R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Clostridium difficile; Metronidazole; Vancomycin

Indexed keywords

VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; INFECTION RISK; LOW DRUG DOSE; MORTALITY; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

CLOSTRIDIUM DIFFICILE; METRONIDAZOLE; VANCOMYCIN;

AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; DIARRHEA; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84889084929     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.08.013     Document Type: Article

References (31)

1. M. Hyland, M. Ofner-Agostini, M. Miller, S. Paton, M. Gourdeau, and M. Ishak Canadian Hospital Epidemiology Committee; Canadian Nosocomial Infection Surveillance Program (Health Canada). N-CDAD in Canada: results of the Canadian Nosocomial Infection Surveillance Program 1997 N-CDAD Prevalence Surveillance Project Can J Infect Dis 12 2001 81 88
2. C.A. Muto, M. Pokrywka, K. Shutt, A.B. Mendelsohn, K. Nouri, and K. Posey A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use Infect Control Hosp Epidemiol 26 2005 273 280
3. S.M. Poutanen, and A.E. Simor Clostridium difficile-associated diarrhea in adults CMAJ 171 2004 51 58
4. L.K. Archibald, S.N. Banerjee, and W.R. Jarvis Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001 J Infect Dis 189 2004 1585 1589
5. M.D. Redelings, F. Sorvillo, and L. Mascola Increase in Clostridium difficile-related mortality rates, United States, 1999-2004 Emerg Infect Dis 13 2007 1417 1419
6. J. Pépin, L. Valiquette, M.E. Alary, P. Villemure, A. Pelletier, and K. Forget Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity CMAJ 171 2004 466 472
7. V.G. Loo, L. Poirier, M.A. Miller, M. Oughton, M.D. Libman, and S. Michaud A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality N Engl J Med 353 2005 2442 2449
8. D.N. Gerding, S. Johnson, L.R. Peterson, M.E. Mulligan, and J. Silva Jr. Clostridium difficile-associated diarrhea and colitis Infect Control Hosp Epidemiol 16 1995 459 477
9. J. Pepin, M.E. Alary, L. Valiquette, E. Raiche, J. Ruel, and K. Fulop Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada Clin Infect Dis 40 2005 1591 1597
10. F.A. Zar, S.R. Bakkanagari, K.M. Moorthi, and M.B. Davis A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity Clin Infect Dis 45 2007 302 307
11. M.P. Bauer, E.J. Kuijper, and J.T. van Dissel European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI) Clin Microbiol Infect 15 2009 1067 1079
12. S.H. Cohen, D.N. Gerding, S. Johnson, C.P. Kelly, V.G. Loo, and L.C. McDonald Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Infect Control Hosp Epidemiol 31 2010 431 455
13. R. Fekety, J. Silva, C. Kauffman, B. Buggy, and H.G. Deery Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens Am J Med 86 1989 15 19
14. M. Gonzales, J. Pepin, E.H. Frost, J.C. Carrier, S. Sirard, and L.C. Fortier Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection BMC Infect Dis 10 2010 363
15. L.V. McFarland, G.W. Elmer, and C.M. Surawicz Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease Am J Gastroenterol 97 2002 1769 1775
16. J.G. Bartlett Narrative review: the new epidemic of Clostridium difficile-associated enteric disease Ann Intern Med 145 2006 758 764
17. D.R. Baird Comparison of two oral formulations of vancomycin for treatment of diarrhoea associated with Clostridium difficile J Antimicrob Chemother 23 1989 167 169
18. R.C. Owens Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists Pharmacotherapy 26 2006 299 311
19. S.N. Bass, S.R. Bauer, E.A. Neuner, and S.W. Lam Comparison of treatment outcomes for vancomycin alone versus combination therapy in severe Clostridium difficile infection [Abstract] Crit Care Med 40 2012 356
20. D.A. Katz, D.W. Bates, E. Rittenberg, A. Onderdonk, K. Sands, and L.A. Barefoot Predicting Clostridium difficile stool cytotoxin results in hospitalized patients with diarrhea J Gen Intern Med 12 1997 57 62
21. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
22. F.L. Ferreira, D.P. Bota, A. Bross, C. Melot, and J.L. Vincent Serial evaluation of the SOFA score to predict outcome in critically ill patients JAMA 286 2001 1754 1758
23. D.M. Musher, N. Logan, A.M. Bressler, D.P. Johnson, and J.F. Rossignol Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study Clin Infect Dis 48 2009 e41 e46
24. R.A. Lucas, W.J. Bowtle, and R. Ryden Disposition of vancomycin in healthy volunteers from oral solution and semi-solid matrix capsules J Clin Pharm Ther 12 1987 27 31
25. S. Roberts, H. Heffernan, N. Al Anbuky, C. Pope, S. Paviour, and T. Camp Molecular epidemiology and susceptibility profiles of Clostridium difficile in New Zealand, 2009 N Z Med J 124 2011 45 51
26. H. Huang, H. Fang, A. Weintraub, and C.E. Nord Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm Clin Microbiol Infect 15 2009 1170 1173
27. F. Barbut, C. Kajzer, N. Planas, and J.C. Petit Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea J Clin Microbiol 31 1993 963 967
28. P.N. Levett Time-dependent killing of Clostridium difficile by metronidazole and vancomycin J Antimicrob Chemother 27 1991 55 62
29. Y.T. Garcia, T.D. Kish, and H.B. Fung Evaluation of clinical cure rates of Clostridium difficile with different oral vancomycin dosing regimens 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 9-12 September 2012 2012 ASM Press San Francisco, CA., Washington, DC [abstract K-919]
30. I. Odenholt, M. Walder, and M. Wullt Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile Chemotherapy 53 2007 267 274
31. T.J. Louie, M.A. Miller, K.M. Mullane, K. Weiss, A. Lentnek, and Y. Golan Fidaxomicin versus vancomycin for Clostridium difficile infection N Engl J Med 364 2011 422 431